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ABSTRACT 
Abnormal metabolism, including abnormal lipid metabolism, is a hallmark of cancer cells. 
Some studies have demonstrated that the lipogenic pathway might promote the 
development of hepatocellular carcinoma (HCC). However, the role of adipose 
triglyceride lipase (ATGL) in hepatocellular carcinoma cells has not been elucidated. We 
evaluated the function of ATGL in hepatocellular carcinoma using methyl azazolyl blue 
and migration assay through overexpression of ATGL in HepG2 cells. Quantitative 
reverse‐transcription polymerase chain reaction and Western blot analyses were used to 
assess the mechanisms of ATGL in hepatocellular carcinoma. In the current study, we 
first constructed and transiently transfected ATGL into hepatocellular carcinoma cells. 
Secondly, we found that ATGL promoted the proliferation of hepatoma cell lines via 
upregulating the phosphorylation of AKT, but did not affect the metastatic ability of HCC 
cells. Moreover, the p‐AKT inhibitor significantly eliminated the effect of ATGL on the 
proliferation of hepatoma carcinoma cells. Taken together, our results indicated that 
ATGL promotes hepatocellular carcinoma cells proliferation through upregulation of the 
AKT signaling pathway. 
Keywords: ATGL, hepatocellular carcinoma cells, p‐AKT signaling pathway, tumor 
proliferation. 
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1. INTRODUCTION 
The occurrence, development, and metastasis of tumors are closely related to fat and 
lipids.1, 2 It is reported that serum lipid abnormalities are one of the high risk factors for 
breast cancer, prostate cancer, and liver cancer,3, 4 but the exact mechanism is not yet 
clear. The triacylglycerols (TGs) in the cell exist in human adipose tissue in the form of 
lipid droplets. When hungry, TGs, stored in fat cells, are hydrolyzed to glycerol and fatty 
acid, and then perform β oxidation to provide energy for the body. The hydrolysis of TGs 
to glycerol and fatty acid requires at least three lipolytic enzymes.5, 6 Adipose triglyceride 
lipase (ATGL) catalyzes the initial step of lipolysis, converting TGs to diacylglycerols 
(DGs); hormone‐sensitive lipase is mainly responsible for the hydrolysis of DGs to 
monoacylglycerols (MGs) and MG lipase (MGL) hydrolyzes MGs.7 ATGL is the newest 
member of the lipolytic enzyme trio. The enzyme, first described in 2004, belongs to the 
family patatin domain‐containing proteins including nine human and eight murine 
members.8, 9 However, the role of ATGL in hepatocellular carcinoma cells is not yet 
clear. The aim of this study was to study the effect of ATGL on hepatocellular carcinoma 
cells by silencing or overexpression of ATGL, and to further elucidate its molecular 
mechanism, providing a theoretical basis and experimental data for the treatment of HCC 
with ATGL as a target in future. 
2 MATERIALS AND METHODS 
2.1 CELL CULTURE 
HepG2 cells were from the existing cell lines in our laboratory. Hep3B was purchased 
from ATCC. Dulbecco's modified Eagle's medium (DMEM)  + 10% fetal bovine serum was 
cultured in an incubator at 37°C and 5% CO2. The logarithmic phase cells were taken for 
follow‐up experiments. 
2.2 ANTIBODIES AND REAGENTS 
Competent bacteria DH5 α was purchased from Takara for overexpression of ATGL 
plasmid construction. pcDNA3.1+ was purchased from Invitrogen as a vector for the over 
expressing ATGL plasmid. Lysogeny broth‐related reagents were purchased from Beijing 
Ding. AKT (catalogue: 4691), p‐AKT (catalogue: 9271) and ATGL (catalogue: 2439) 
 
 
antibodies were purchased from CST, and β‐actin antibody was purchased from Sigma. 
The p‐AKT inhibitor MK2206 (catalogue: HY‐10385) was purchased from MCE. Two 
methyl sulfoxide (dimethyl sulfoxide, DMSO), four methyl azazolyl blue (MTT) and 4% 
polyoxymethylene (paraformaldehyde) were purchased from Beijing Ding Guo company; 
the ECL chemiluminescence kit was bought from Beijing Pulilai. The transfection reagent 
Lipo2000 was purchased from Invitrogen. 
2.3 WESTERN BLOT ANALYSIS 
Proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
and transferred onto a polyvinylidene fluoride membrane. The membranes were 
incubated in 5% nonfat dry milk, followed by incubation with a primary antibody against 
ATGL (1:1000), AKT (1:1000), p‐AKT (1:1000), β‐actin (1:10000) and a secondary 
antibody. Membranes were developed using Clarity Western ECL. 
2.4 CONSTRUCTION OF ATGL‐PCDNA3.1 + OVEREXPRESSED PLASMIDS 
1) Primer design 
The cDNA sequence of human ATGL was obtained from PubMed, and then ATGL 
primers were designed according to pcDNA3.1 (+) carrier information. The list of primer 
sequences is shown in Table 1. 
Table 1. Primer sequences of ATGL PCR produces 
Primer name Primer sequences Restriction 
site 
Forward 
primer 
5'‐CCCAAGCTT ATGTTTCCCCCGCGAGAAGACG ‐3' HindIII 
Reverse 
primer 
5'‐CCGGAATTC CAGCCCCAGGGCCCCGATCACGG‐
3' 
EcoRI 
 
 
Abbreviations: ATGL, adipose triglyceride lipase; qRT‐PCR, quantitative reverse‐
transcription polymerase chain reaction. 
2) PCR fishing of target gene and enzyme cut and connection 
cDNA was used as a template from the hepatoma cell HepG2. The ATGL gene was 
extracted using PCR by specific primers, and then used for enzyme digestion, linkage, 
and identification. 
3) Transfection of ATGL‐overexpression plasmid 
The transfection reagent was Lipo2000 (Invitrogen company). The detailed operation 
steps are described in the instruction manual. In brief, after transfection for 4 to 6 hours, 
the cells were converted to the normal culture medium, and the protein or RNA was 
analyzed at different time points. 
2.5 DETERMINATION OF CELL PROLIFERATION ACTIVITY BY MTT ASSAY 
The HepG2 or Hep3B cells were inoculated in 96 plates transiently transfected with ATGL 
plasmid or siRNA for ATGL. MTT working fluid was added (the concentration of 5 mg/mL) 
and cultured for 4 hours followed by removing the supernatant. 250 μL DMSO was added 
to each hole and determined with an instrument in 570 nm. All the experiments were 
repeated three times. 
2.6 QUANTITATIVE REVERSE‐TRANSCRIPTION POLYMERASE CHAIN REACTION 
Quantitative reverse‐transcription polymerase chain reaction (RT‐PCR) was used by 
means of an ABI fluorescence quantitative PCR instrument. The reagent was SYBR 
Green I from Takara. The primers were designed by a Shanghai‐based company, as 
shown in Table 2. 
 
 
 
 
 
 
Table 2. qRT‐PCR sequences 
Gene Forward primers Reverse primers 
ATGL 5′‐GGCCAGACCCAGCTTCTTC‐3′ 5′‐GCCAGGCCTCTGTGAGC‐3′ 
β‐Actin 5′‐GCACTCTTCCAGCCTTCCTT‐3′ 5′‐GTTGGCGTACAGGTCTTTGC‐3′ 
 
Abbreviations: ATGL, adipose triglyceride lipase; qRT‐PCR, quantitative reverse‐
transcription polymerase chain reaction. 
The Real‐time PCR reaction conditions are as follows: 
Two step method: 95°C, 30 s; 1 cycle. PCR reaction, 95°C, 5 s; 60°C, 15 s; 45 cycles; 
dissolution, 95°C, 5 s; 65°C, 20 s; 95°C, 5 s; 1 cycle. After the end of PCR, the relative 
standard analysis method was used to correct the standard curve, and finally the 
transcriptional level of each gene was calculated. 
2.7 MIGRATION ASSAY 
Migration of HepG2 cells were examined using 24‐well Boyden chambers (Corning, 
Corning, NY) with 8 μm inserts. Briefly, the serum‐starved cells were trypsinized and 
plated at the upper chamber at 2 × 104 cells per well, together with serum‐free DMEM and 
10% fetal bovine serum placed in the lower chamber. The cells were then allowed to 
migrate for 12 hours at 37℃. After the incubation, nonmigrating cells were removed from 
the upper chamber with a cotton swab, and the membrane inserts were stained with 
crystal violet solution. 
2.8 STATISTICAL ANALYSIS 
T‐test was used for comparative analysis, and P less than .05 was significantly different. 
All the experiments were repeated three times. 
 
 
 
 
 
3 RESULTS 
3.1 ATGL CONSTRUCTION AND OVEREXPRESSION IN HEPATOCELLULAR 
CARCINOMA CELLS 
To study the effect of ATGL on hepatocellular carcinoma, we first constructed the ATGL 
plasmid. HepG2 cell cDNA was used as template for amplication of ATGL CDS sequence 
by PCR. The result for the ATGL fragment is shown in Figure 1A. To verify the successful 
overexpression of ATGL plasmid in hepatoma cells, HepG2 was transfected with the 
ATGL plasmid, and validated by Western blot analysis and real‐time fluorescent 
quantitative PCR. The results showed that the ATGL plasmid was successfully 
transfected into hepatocellular carcinoma (HCC) cells, and highly expressed (Figure 1B 
and 1C). 
Figure 1.  
 
ATGL construction and overexpression in hepatocellular carcinoma cells. A, Agarose 
electrophoresis was used to identify the PCR amplification products of ATGL. 1, DNA 
maker; 2‐7, the annealing temperature is 55, 58, 61, 64, 67, 70°C in turn. B, ATGL was 
transfected into HepG2 cells after 24 hours and protein was collected. Western blot 
analysis was used to detect the ATGL level with β‐Actin as the loading control. C, The 
transcriptional level of ATGL was detected by qRT‐PCR. ATGL was transfected into 
HepG2 cells for 24 hours and RNA was extracted. **P  < .001. ATGL, adipose triglyceride 
 
 
lipase; CON, control; PCR, polymerase chain reaction; qRT‐PCR, quantitative reverse‐
transcription PCR 
3.2 ATGL PROMOTES THE PROLIFERATION OF HEPATOCELLULAR CARCINOMA 
CELLS 
To study the effect of ATGL on hepatocellular carcinoma, we overexpressed ATGL in the 
hepatoma cell line HepG2 and detected the proliferation ability of HepG2 by MTT assay. 
MTT experiments showed that ATGL significantly promoted the proliferation of 
hepatocellular carcinoma (Figure 2A). To fully illustrate the role of ATGL in promoting the 
proliferation of hepatoma cells, we also tested the effect of ATGL on the Hep3B cell line. 
Consistent with the results on HepG2, overexpression of ATGL also promoted the 
proliferation of Hep3B (Figure 2B). Furthermore, overexpression of ATGL increased the 
proliferation of HepG2 by colony formation assay (Figure S1). Moreover, knocking down 
with siRNA for ATGL inhibited cell proliferation (Figure S2), which fully demonstrated that 
ATGL promoted the proliferation of HCC. 
Figure 2. 
 
ATGL promotes the proliferation of hepatocellular carcinoma cells. A, MTT assay was 
used to detect the proliferation of Hep3B cells. Hep3B cells were transfected with ATGL 
plasmid for 24, 48 and 72 hours, and then we detected the proliferative ability of Hep3B 
cells. **P   <  .01. B, MTT assay was used to detect the proliferation of HepG2 cells. 
HepG2 cells were transfected with ATGL plasmid for 24, 48, and 72 hours, and then we 
detected the proliferative ability of HepG2 cells. ATGL, adipose triglyceride lipase; MTT, 
methyl azazolyl blue. **P   <  .01 
 
 
3.3 ATGL DOES NOT AFFECT THE MIGRATION OF HEPATOMA CELLS 
To evaluate the effect of ATGL on the migration ability of hepatoma cells, we also carried 
out the Migration assay. The migration assay involves experimentation with the Boyden 
Transwell cell. After the treated cells were digested, the cells were planted in the Boyden 
Transwell compartment with serum‐free medium and 10% fetal bovine serum under the 
chamber. The cells in the chamber migrated through the chamber hole to the lower 
chamber, and the greater the cell number that passed through the chamber, the stronger 
the migration energy. After transfection of ATGL plasmid for 24 hours, the cells were 
digested and cultured in the Boyden Transwell, and the number of cells passing through 
the Boyden Transwell was detected at different times. Migration assay results showed 
that overexpression of ATGL did not affect the migration ability of HepG2 cells (Figure 3A 
and 3B), compared with the control group. 
Figure 3. 
 
The metastasis of the hepatocellular carcinoma cell. A, Migration assay was used to 
detect the effect of ATGL on the migration of HepG2 cells. Transfection of ATGL plasmid 
 
 
for 24 hours, the cells were digested and cultured in Boyden Transwell chamber. B, The 
number of HepG2 cells passing through the Boyden Transwell chamber was counted. 
ATGL, adipose triglyceride lipase; CON, control 
3.4 ATGL UPREGULATED THE LEVEL OF PHOSPHORYLATION OF AKT 
The p‐AKT signaling pathway plays an important role in tumorigenesis, proliferation, 
metastasis, and invasion. To further study the molecular mechanism of ATGL promoting 
the proliferation of HCC, we detected the p‐AKT signaling pathway. We found that the 
overexpression of ATGL significantly upregulated the level of phosphorylation of AKT 
(Figure 4), indicating that ATGL promotes the proliferation of hepatoma carcinoma cells 
by regulating the p‐AKT signaling pathway. To further verify that ATGL promotes the 
proliferation of hepatoma carcinoma cells through the AKT signaling pathway, we used 
the p‐AKT inhibitor to treat cells and then performed the MTT assay. The results showed 
that the p‐AKT inhibitor significantly eliminated the effect of ATGL on the p‐akt level and 
proliferation of hepatoma carcinoma cells (Figures 4 and 5). 
Figure 4. 
 
ATGL upregulated the level of phosphorylation of AKT. ATGL promotes the 
phosphorylation of AKT. ATGL plasmid was overexpressed in HepG2 cells for 24 hours, 
and the p‐AKT and AKT levels were detected by Western blot analysis. β‐Actin as loading 
control. ATGL, adipose triglyceride lipase; CON, control. 
 
 
 
Figure 5. 
 
ATGL promotes the proliferation of hepatocellular carcinoma cells via the p‐AKT signaling 
pathway. A, MTT assay was used to detect the proliferation of Hep3B cells. Hep3B cells 
were transfected with ATGL plasmid for 24 hours, and then the p‐AKT inhibitor was 
treated for 12  hours. B, MTT assay was used to detect the proliferation of HepG2 cells. 
HepG2 cells were transfected with ATGL plasmid for 24 hours, and then the p‐AKT 
inhibitor was treated for 12 hours. *P  < .05; **P  < .001. ATGL, adipose triglyceride lipase; 
CON, control; MTT, methyl azazolyl blue. 
4. DISCUSSION 
The intracellular fat is mainly in the form of lipid droplets. ATGL is the first enzyme for fat 
degradation, which degrades fat to monoacylglycerols (MGs) and starts the fat 
mobilization.10, 11 It is found that abnormal metabolism of lipids is closely related to the 
biological processes such as tumor occurrence, development, metastasis, and so on.3, 
4 However, the role of ATGL in regulating lipid metabolism and the tumor is still not clear. 
To study the role of ATGL in hepatocellular carcinoma cells, we first constructed the 
overexpression plasmid of ATGL. The pcDNA3.1+ vector is the most commonly used 
expression vector, highly expressed in eukaryotic cells, and is suitable for various gene 
 
 
expressions. So we chose pcDNA3.1+ as a vector to construct the ATGL overexpression 
plasmid. 
We first extracted RNA from the hepatocellular carcinoma cell HepG2, and reversed to 
cDNA, as a template to catch the target gene of ATGL. We designed specific primers 
based on the CDS region of the human ATGL gene on PubMed and added HindIII and 
EcoRI restriction sites at the ends of the primers. For catching ATGL gene fragments, we 
designed different annealing temperatures. The agarose electrophoresis results showed 
that the ATGL target gene fragment could be found from the annealing temperature of 
55°C to 70°C. The brightest ATGL band (Figure 1) at the annealing temperature was 
67°C (Figure 1), indicating that the 67°C was the best annealing temperature. 
Subsequently, we inserted the ATGL gene into the pcDNA3.1+ vector by molecular 
cloning steps such as enzyme digestion, linkage, and transformation. Furthermore, we 
transfected the ATGL plasmid into the hepatocellular carcinoma cell line HepG2 and 
verified its expression in HepG2. We selected Lipo2000 as a transfection agent and 
transfected the ATGL plasmid for 24 hours to collect RNA and protein. Quantitative RT‐
PCR and Western blot analyses were used to evaluate the transcriptional and protein 
level of ATGL plasmid in HepG2. After 24 hours transfection of ATGL, the transcriptional 
level of ATGL was nearly 20000 times as high as that of the control group, indicating that 
the ATGL plasmid was highly expressed in the hepatoma cell HepG2, which established 
the basis for the next step of research on ATGL. In addition, the ATGL protein level was 
highly expressed, which was consistent with the transcriptional level. 
To verify the effect of ATGL on tumor, we overexpressed ATGL in the hepatoma cell line 
HepG2, and MTT method was used to detect the growth ability of HepG2 cells. We found 
that the transfection of ATGL plasmids significantly promoted the growth of HepG2 cells 
(Figure 2). At the same time, we also assessed the function of ATGL in the Hep3B 
hepatoma cells. The results showed that ATGL also promoted the growth of Hep3B cells, 
which was consistent with the results of HepG2 cells, indicating that ATGL promoted the 
growth of tumor cells. Our result is consistent with the results of Zagani R's research,12 
which showed that blocking ATGL with the ATGL inhibitor GOS2 or the ATGL small 
interfering fragment inhibited the growth of non–small‐cell lung cancer. But recently, Al‐
 
 
Zoughbi et al13 have found that ATGL is lowly expressed in breast cancer, gastric cancer 
and non–small cell lung cancer, and the absence of ATGL could lead to the occurrence 
of tumor, indicating that ATGL could induce the tumor to occur and inhibit the proliferation 
of tumor. the This contradiction need to be studied further. In addition, we also studied 
the effect of ATGL on the metastasis of HCC. The migration assay showed that ATGL 
had no effect on the migration of HCC, suggesting that the effect of ATGL on HCC mainly 
promoted the proliferation of the cancer cell without affecting the migration of the cancer 
cell. Based on the above phenomenon, we will next focus on the molecular mechanism 
of ATGL promoting the proliferation of hepatocellular carcinoma. 
Tumor growth and proliferation are closely related to the p‐AKT signaling pathway.14, 15 
Next, we will study whether ATGL promotes tumor growth through the p‐AKT signaling 
pathway. Our results shown that ATGL significantly upregulated the level of 
phosphorylation of AKT, indicating that ATGL promotes the growth of tumor cells through 
the p‐AKT signaling pathway, which is consistent with the research reported that p‐AKT 
promotes the proliferation of HCC.16, 17 
5. CONCLUSION 
The current paper reveals the role of ATGL in HCC and elucidates its molecular 
mechanism, which provides a theoretical basis and experimental data for future targeting 
of ATGL in HCC therapies. 
ACKNOWLEDGMENT 
This study was supported by the Laboratory Opening Project of Guangzhou Medical 
University Students (Grant Numbers: B185004039), the Western Medicine Guide Project 
of Guangzhou Municipal Health Bureau (Grant numbers: 20171A011312); Guangzhou 
Traditional Chinese Medicine, integrated traditional Chinese and Western Medicine 
Science and Technology Project (Grant numbers: 20182A011020) and research project 
on elite talent training of the Third Affiliated Hospital of Guangzhou Medical University. 
CONFLICT OF INTERESTS 
The authors declare that there are no conflicts of interests. 
 
 
AUTHOR CONTRIBUTIONS 
M.L., X.Y., and K.W. were responsible for the cell experiment; Y.X. and H.H. were 
responsible for experimental design and guidance. 
REFERENCES 
1. Grundy, S. M. (2004). Obesity, Metabolic Syndrome, and Cardiovascular Disease. The 
Journal of Clinical Endocrinology & Metabolism, 89(6), 2595–2600. 
https://doi.org/10.1210/jc.2004-0372 
2. Glass, C. K., & Witztum, J. L. (2001). Atherosclerosis: The Road Ahead. Cell, 104(4), 
503–516. https://doi.org/10.1016/S0092-8674(01)00238-0 
3. Hsu, P. P., & Sabatini, D. M. (2008). Cancer Cell Metabolism: Warburg and Beyond. Cell, 
134(5), 703–707. https://doi.org/10.1016/j.cell.2008.08.021 
4. Rysman, E., Brusselmans, K., Scheys, K., Timmermans, L., Derua, R., Munck, S., 
Veldhoven, P. P. V., Waltregny, D., Daniëls, V. W., Machiels, J., Vanderhoydonc, F., 
Smans, K., Waelkens, E., Verhoeven, G., & Swinnen, J. V. (2010). De novo Lipogenesis 
Protects Cancer Cells from Free Radicals and Chemotherapeutics by Promoting 
Membrane Lipid Saturation. Cancer Research, 70(20), 8117–8126. 
https://doi.org/10.1158/0008-5472.CAN-09-3871 
5. Liu, P., Ying, Y., Zhao, Y., Mundy, D. I., Zhu, M., & Anderson, R. G. W. (2004). Chinese 
Hamster Ovary K2 Cell Lipid Droplets Appear to Be Metabolic Organelles Involved in 
Membrane Traffic. Journal of Biological Chemistry, 279(5), 3787–3792. 
https://doi.org/10.1074/jbc.M311945200 
6. Schaffer, J. E. (2003). Lipotoxicity: When tissues overeat. Current Opinion in Lipidology, 
14(3), 281–287. 
7. Haemmerle, G., Lass, A., Zimmermann, R., Gorkiewicz, G., Meyer, C., Rozman, J., 
Heldmaier, G., Maier, R., Theussl, C., Eder, S., Kratky, D., Wagner, E. F., Klingenspor, 
M., Hoefler, G., & Zechner, R. (2006). Defective Lipolysis and Altered Energy Metabolism 
in Mice Lacking Adipose Triglyceride Lipase. Science, 312(5774), 734–737. 
https://doi.org/10.1126/science.1123965 
8. Jocken, J. W. E., Smit, E., Goossens, G. H., Essers, Y. P. G., van Baak, M. A., Mensink, 
M., Saris, W. H. M., & Blaak, E. E. (2008). Adipose triglyceride lipase (ATGL) expression 
 
 
in human skeletal muscle is type I (oxidative) fiber specific. Histochemistry and Cell 
Biology, 129(4), 535–538. https://doi.org/10.1007/s00418-008-0386-y 
9. Reid, B. N., Ables, G. P., Otlivanchik, O. A., Schoiswohl, G., Zechner, R., Blaner, W. S., 
Goldberg, I. J., Schwabe, R. F., Chua, S. C., & Huang, L.-S. (2008). Hepatic 
Overexpression of Hormone-sensitive Lipase and Adipose Triglyceride Lipase Promotes 
Fatty Acid Oxidation, Stimulates Direct Release of Free Fatty Acids, and Ameliorates 
Steatosis. Journal of Biological Chemistry, 283(19), 13087–13099. 
https://doi.org/10.1074/jbc.M800533200 
10. Sunny, N. E., Parks, E. J., Browning, J. D., & Burgess, S. C. (2011). Excessive Hepatic 
Mitochondrial TCA Cycle and Gluconeogenesis in Humans with Nonalcoholic Fatty Liver 
Disease. Cell Metabolism, 14(6), 804–810. https://doi.org/10.1016/j.cmet.2011.11.004 
11. Satapati, S., Sunny, N. E., Kucejova, B., Fu, X., He, T. T., Méndez-Lucas, A., Shelton, J. 
M., Perales, J. C., Browning, J. D., & Burgess, S. C. (2012). Elevated TCA cycle function 
in the pathology of diet-induced hepatic insulin resistance and fatty liver. Journal of Lipid 
Research, 53(6), 1080–1092. https://doi.org/10.1194/jlr.M023382 
12. Zagani, R., El-Assaad, W., Gamache, I., & Teodoro, J. G. (2015). Inhibition of adipose 
triglyceride lipase (ATGL) by the putative tumor suppressor G0S2 or a small molecule 
inhibitor attenuates the growth of cancer cells. Oncotarget, 6(29), 28282–28295. 
13. Al-Zoughbi, W., Pichler, M., Gorkiewicz, G., Guertl-Lackner, B., Haybaeck, J., Jahn, S. 
W., Lackner, C., Liegl-Atzwanger, B., Popper, H., Schauer, S., Nusshold, E., Kindt, A. S. 
D., Trajanoski, Z., Speicher, M. R., Haemmerle, G., Zimmermann, R., Zechner, R., 
Vesely, P. W., & Hoefler, G. (2016). Loss of adipose triglyceride lipase is associated with 
human cancer and induces mouse pulmonary neoplasia. Oncotarget, 7(23), 33832–
33840. https://doi.org/10.18632/oncotarget.9418 
14. Xue, D., Zhou, C., Lu, H., Xu, R., Xu, X., & He, X. (2016). LncRNA GAS5 inhibits 
proliferation and progression of prostate cancer by targeting miR-103 through AKT/mTOR 
signaling pathway. Tumor Biology, 37(12), 16187–16197. 
https://doi.org/10.1007/s13277-016-5429-8 
15. Yang, B., Yan, P., Gong, H., Zuo, L., Shi, Y., Guo, J., Guo, R., Xie, J., & Li, B. (2016). 
TWEAK protects cardiomyocyte against apoptosis in a PI3K/AKT pathway dependent 
manner. American Journal of Translational Research, 8(9), 3848–3860. 
 
 
16. Tu, K., Liu, Z., Yao, B., Han, S., & Yang, W. (2016). MicroRNA-519a promotes tumor 
growth by targeting PTEN/PI3K/AKT signaling in hepatocellular carcinoma. International 
Journal of Oncology, 48(3), 965–974. https://doi.org/10.3892/ijo.2015.3309 
17. Hsieh, Y.-H., Hsieh, S.-C., Lee, C.-H., Yang, S.-F., Cheng, C.-W., Tang, M.-J., Lin, C.-L., 
Lin, C.-L., & Chou, R.-H. (2015). Targeting EMP3 suppresses proliferation and invasion 
of hepatocellular carcinoma cells through inactivation of PI3K/Akt pathway. Oncotarget, 
6(33), 34859–34874. 
 
 
 
